Cite
Safety and on-treatment efficacy of telaprevir: the early access programme for patients with advanced hepatitis C
MLA
Inmaculada Fernández, et al. “Safety and On-Treatment Efficacy of Telaprevir: The Early Access Programme for Patients with Advanced Hepatitis C.” Gut, vol. 63, Nov. 2013, pp. 1150–58. EBSCOhost, widgets.ebscohost.com/prod/customlink/proxify/proxify.php?count=1&encode=0&proxy=&find_1=&replace_1=&target=https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&scope=site&db=edsair&AN=edsair.doi.dedup.....4401a1a5cdcc43f1ae9e72fd59ad5940&authtype=sso&custid=ns315887.
APA
Inmaculada Fernández, Wafae Iraqi, Heiner Wedemeyer, D. Abdurakhmanov, I. Lonjon-Domanec, Christophe Moreno, M.L. Colombo, Ralph DeMasi, J.M. Läuffer, Simone I. Strasser, A. Verheyen, Petr Urbánek, Paulo Roberto Abrão Ferreira, Adrian Streinu-Cercel, & Andrew Martin Hill. (2013). Safety and on-treatment efficacy of telaprevir: the early access programme for patients with advanced hepatitis C. Gut, 63, 1150–1158.
Chicago
Inmaculada Fernández, Wafae Iraqi, Heiner Wedemeyer, D. Abdurakhmanov, I. Lonjon-Domanec, Christophe Moreno, M.L. Colombo, et al. 2013. “Safety and On-Treatment Efficacy of Telaprevir: The Early Access Programme for Patients with Advanced Hepatitis C.” Gut 63 (November): 1150–58. http://widgets.ebscohost.com/prod/customlink/proxify/proxify.php?count=1&encode=0&proxy=&find_1=&replace_1=&target=https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&scope=site&db=edsair&AN=edsair.doi.dedup.....4401a1a5cdcc43f1ae9e72fd59ad5940&authtype=sso&custid=ns315887.